Sparks - Oryzon Genomics

Oryzon Genomics has announced the expansion of its patent portfolio for its two clinical-stage drug candidates, iadademstat and vafidemstat. The Australian Patent Office has issued a ‘Decision to Grant’ communication for the patent ‘Combinations of iadademstat for cancer therapy’, allowing claims cover combinations of iadademstat with PD1 or PD-L1 inhibitors in cancer treatment. This includes small-cell lung cancer, a target of one of Oryzon’s key oncology programmes. Once granted, this Australian patent will remain in place until at least 2040, excluding any potential additional patent term extensions. This latest update also noted that a corresponding patent has been granted in Russia, and applications are pending in Europe, the US, Japan, China and other key regions.

Oryzon has also received a ‘Decision to Grant’ communication from the European Patent Office for its patent application ‘Vafidemstat for treating behavior alterations’, covering the use of vafidemstat to manage aggression and social withdrawal associated with conditions of the central nervous system. Among the allowed claims, there are some specifically covering the treatment of aggressiveness associated with borderline personality disorder, autism spectrum disorder (ASD), Alzheimer’s disease (alongside and other conditions), as well as claims directed to treating social withdrawal associated with diseases such as schizophrenia or ASD. Once granted, this European patent will remain in place until at least 2038, excluding any other potential patent term extensions. Additional patents in this family have already been granted, or allowed, in Europe, Australia, Canada, Hong Kong, Israel, South Korea, Malaysia, the Philippines and Russia, with applications pending in other key regions.